Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry

Jong Man Kim, Deok Gie Kim, Jihyun Kim, Keunsung Lee, Kwang-Woong Lee, Je Ho Ryu, Bong-Wan Kim, Dong Lak Choi, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Koo Jeong Kang, Jai Young Cho, Geun Hong, Hee Chul Yu, Ju Ik Moon, Dongho Choi, Shin Hwang, Myoung Soo Kim

Clin Mol Hepatol. 2021;27(3):451-462. Published online February 2, 2021

DOI: https://doi.org/10.3350/cmh.2020.0292

View: 7747 Download: 318 Web of Science: 34 Crossref: 37

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

Desmond Y. H. Yap, Kevin S. H. Liu, Yu-Chun Hsu, Grace L. H. Wong, Ming-Chang Tsai, Chien-Hung Chen, Ching-Sheng Hsu, Yee Tak Hui, Michael K. K. Li, Chen-Hua Liu, Yee-Man Kan, Ming-Lung Yu, Man-Fung Yuen

Clin Mol Hepatol. 2020;26(4):554-561. Published online August 28, 2020

DOI: https://doi.org/10.3350/cmh.2020.0058

View: 5678 Download: 169 Web of Science: 8 Crossref: 8

Editorial

More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis

Paul Kwo, Deepti Dronamraju

Clin Mol Hepatol. 2020;26(4):489-491. Published online September 24, 2020

DOI: https://doi.org/10.3350/cmh.2020.0228

View: 4228 Download: 73 Web of Science: 1 Crossref: 1

1 |

Viewed By 5014	MAFLD: How is it different from NAFLD?
Viewed By 4843	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4791	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4496	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4466	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search